Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia
Lu AE58054 has shown positive results in a number of preclinical trials, which documented the compound's ability to improve cognition. Affecting other areas of the brain than traditional anti-psychotics, the compound has an effect that breaks with tradition. In this way, Lu AE58054 complements the existing anti-psychotics by improving the general clinical efficacy of the overall treatment. Consequently, Lundbeck expects that Lu AE58054 will improve the daily functioning of the patients and for example improve their ability to solve practical problems in their daily lives.
Based on the positive preclinical data and positive outcomes of phase I trials in healthy individuals, Lundbeck has now launched a phase II trial with two treatment groups of 60 patients each. The first group will receive treatment with risperidone and placebo, while the other will receive risperidone and Lu AE58054. The treatment period will run for three months. The trial has just been initiated, and preliminary results are expected by the end of 2009.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.